Article
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer.
Asia-Pacific journal of clinical oncology - 1 Oct 2022
Chong Chia Yuen, Jalali Azim, Wong Hui Li, Loft Matthew, Wong Rachel, Lee Margaret, Gately Lucy, Hong Wei, Shapiro Jeremy, Kosmider Suzanne, Tie Jeannie, Ananda Sumitra, Yeung Justin M, Ma Brigette, Burge Matthew, Jennens Ross, Tran Ben, Lee Belinda, Lim Lionel, Dean Andrew, Nott Louise, Gibbs Peter
Abstract excerpt
BACKGROUND: RAS mutation testing now routinely informs the optimal management of metastatic colorectal cancer (mCRC), specifically the finding of a RAS mutation defines patients who will not benefit from treatment with an epidermal growth factor receptor inhibitor. Over time more RAS genes have been tested and more sensitive techniques used. AIMS: To review routine care RAS testing and results over time. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.